CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2007
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246190/ |